Blood Pressure Alterations in CML Patients Treated with Imatinib vs. Nilotinib : A Clinical Insight
References
- OSMAN AEG, DEININGER MW. Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions. Blood Rev 2021;49.
- REKSODIPUTRO A H. Epidemiology Study and Mutation Profile of Patients with Chronic Myeloid Leukemia (CML) in Indonesia. J Blood Disord Transfus 2015;06.
- CORTES J, PAVLOVSKY C, SAUßELE S. Chronic myeloid leukaemia. The Lancet 2021;398:1914–26.
- GUSTAFSON D, FISH JE, LIPTON JH, et al. Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia. Curr Hematol Malig Rep 2020;15:20–30.
- JABBOUR E, KANTARJIAN H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol 2020;95:691–709.
- JAIN P, KANTARJIAN H, BODDU PC, et al. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv 2019;3:851–61.
- MULAS O, CAOCCI G, MOLA B, et al. Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis. Front Pharmacol 2021;12.
- COSTA A, PITTORRU R, CAOCCI G, et al. The Direct and Indirect Effects of Tyrosine Kinase Inhibitors on the Cardiovascular System in Chronic Myeloid Leukemia. Hemato 2023;4:207–26.
- COHEN JB, BROWN NJ, BROWN SA, et al. Cancer Therapy-Related Hypertension: A Scientific Statement from the American Heart Association. Hypertension 2023;80:E46–57.
- JOHNSON HM, SHIMBO D, ABDALLA M, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension 2025;82:e212–316.
- MINCIACCHI VR, KUMAR R, KRAUSE DS. Chronic myeloid leukemia: A model disease of the past, present and future. Cells 2021;10:1–23.
- BATAR P, ALIZADEH H, ROKSZIN G, et al. Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary. Pathology and Oncology Research 2024;30.
- HÖGLUND M, SANDIN F, SIMONSSON B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol 2015;94:241–7.
- MILOJKOVIC D, LYON AR, MEHTA P, et al. Cardiovascular risk in chronic myeloid leukaemia: A multidisciplinary consensus on screening and management. Eur J Haematol 2023;111:201–10.
- AGARWAL M, THAREJA N, BENJAMIN M, et al. Tyrosine Kinase Inhibitor-Induced Hypertension. Curr Oncol Rep 2018;20.
- HUANG CE, LEE K DER, CHANG JJ, et al. Association of Nilotinib With Cardiovascular Diseases in Patients With Chronic Myelogenous Leukemia: A National Population-Based Cohort Study. Oncologist 2024;29:E81–9.
- HOCHHAUS A, SAGLIO G, HUGHES TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016;30:1044–54.
Language: English
Submitted on: Feb 19, 2026
Published on: Apr 6, 2026
Published by: N.G. Lupu Internal Medicine Foundation
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2026 Wardiyanti Anwar, Tutik Harjianti, Pendrik Tandean, Syakib Bakri, Faridin Hp, Andi Alfian Zainuddin, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.